The global demand for Cell Viability Assays Market is presumed to reach the market size of nearly USD 5.46 BN by 2028 from USD 2.15 BN in 2021 with a CAGR of 10.94% under the study period 2022 - 2028.
Cell viability assays are a technique used to assess cells' general well-being and measure other aspects of cell survival. It is a homogenous method that counts the number of living and dead cells present in a sample regardless of the cell cycle phase. Alternatively, cell viability assays evaluate the capacity of organs, cells, or tissues to increase viability. The ratio of total live cells to total cells is used to determine the cell viability assay. A rise in cell viability denotes cell expansion, while a fall in viability denotes the compound's toxicity.
Market Dynamics
Rising expenditure to develop healthcare infrastructure coupled with rising research and development proficiencies to make technological advancements have fuelled the market growth. The growing prevalence of infectious diseases and chronic disorders will propel the growth in the demand for cell viability assays. The rising geriatric population and changing lifestyles are other indirect cell viability assays market growth determinants. However, the lack of technical experts and professionals to run these processes will challenge the growth of the cell viability assay market in the forecast period mentioned. Moreover, the high cost of instruments may impede the market growth rate. Nonetheless, increasing FDA approvals, clinical trials, and strategic initiatives such as collaborations by major market players are boosting industry growth.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of cell viability assays. The growth and trends of cell viability assays industry provide a holistic approach to this study.
Market Segmentation
This section of the cell viability assays market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Product
- Consumables (Reagents And Assay Kits, By Type, Microplates)
- Instruments (Spectrophotometer Microscopy, Cell Imaging And Analysis System, Flow Cytometry, Others)
By Application
- Drug Discovery And Development
- Stem Cell Research
- Diagnostics
By End-User
- Biopharmaceutical & Pharmaceutical Companies
- CROs & CMOs
- Academic & Research Institutes
- Diagnostic Labs
Regional Analysis
This section covers the regional outlook, which accentuates current and future demand for the Cell Viability Assays market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global Cell Viability Assays Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the cell viability assays market include Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Merck KGaA, BD, PerkinElmer Inc., Promega Corporation, Biotium, Creative Bioarray, Abcam plc, Charles River Laboratories. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
